The new European guidelines for prevention of cardiovascular disease are misleading

被引：13

作者：

Ravnskov, Uffe ^{[1
]}

Alabdulgader, Abdullah ^{[2
]}

de Lorgeril, Michel ^{[3
]}

Diamond, David M. ^{[4
,5
,6
]}

Hama, Rokuro ^{[7
]}

Hamazaki, Tomohito ^{[8
]}

Hammarskjold, Bjorn ^{[9
]}

Harcombe, Zoe ^{[10
]}

Kendrick, Malcolm ^{[11
]}

Langsjoen, Peter ^{[12
]}

McCully, Kilmer S. ^{[13
]}

Okuyama, Harumi ^{[14
]}

Sultan, Sherif ^{[15
]}

Sundberg, Ralf ^{[16
]}

机构：

[1] Magle Stora Kyrkogata 9, Lund, Sweden

[2] Prince Sultan Cardiac Ctr, Al Hufuf, Alhasar, Saudi Arabia

[3] Univ Grenoble Alpes, Fac Med, CNRS, Lab Coeur & Nutr,TIMC, La Tronche, France

[4] Univ S Florida, PCD 4118G, Dept Psychol, Tampa, FL 33620 USA

[5] Univ S Florida, PCD 4118G, Dept Mol Pharmacol, Tampa, FL 33620 USA

[6] Univ S Florida, PCD 4118G, Dept Physiol, Tampa, FL 33620 USA

[7] Japan Inst Pharmacovigilance, Osaka, Japan

[8] Univ Toyama, Toyama Jonan Onsen Daini Hosp, Dept Internal Med, Toyama, Japan

[9] Stromstad Acad, Ostervala, Sweden

[10] Church Farm, Llanvaches, Gwent, Wales

[11] 24 Prestwick Close, Macclesfield, Cheshire, England

[12] 1107 Doctors Dr, Tyler, TX USA

[13] Harvard Med Sch, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA

[14] Nagoya City Univ, Fac Pharmaceut Sci, Midori Ku, 1-89 Kaminokura, Nagoya, Aichi, Japan

[15] Natl Univ Ireland, Dept Vasc & Endovasc Surg, Galway, Ireland

[16] Verandastigen 3, Ronninge, Sweden

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2020年 / 13卷 / 12期

关键词：

Cholesterol; cardiovascular; guidelines; statin; diabetes; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; SERUM-CHOLESTEROL; DOSE SIMVASTATIN; CORONARY EVENTS; RISK; INDIVIDUALS; PRAVASTATIN; THERAPY;

D O I：

10.1080/17512433.2020.1841635

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: The European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) have recently published three major revisions of their guidelines for the management of chronic heart disease, blood lipids, and diabetes. Areas covered: We have scrutinized these guidelines in detail and found that the authors have ignored many studies that are in conflict with their conclusions and recommendations. Expert commentary: The authors of the guidelines have ignored that LDL-cholesterol (LDL-C) of patients with acute myocardial infarction is lower than normal; that high cholesterol is not a risk factor for diabetics; that the degree of coronary artery calcification is not associated with LDL-C; and that 27 follow-up studies have shown that people with high total cholesterol or LDL-C live just as long or longer than people with low cholesterol. They have also ignored the lack of exposure-response in the statin trials; that several of these trials have been unable to lower CVD or total mortality; that no statin trial has succeeded with lowering mortality in women, elderly people, or diabetics; and that cholesterol-lowering with statins has been associated with many serious side effects.

引用

页码：1289 / 1294

页数：6

共 58 条

[11] Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review [J].